The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Full enrollment results from an extended phase I, multicenter, open label study of marizomib (MRZ) with temozolomide (TMZ) and radiotherapy (RT) in newly diagnosed glioblastoma (GBM).
 
Warren P. Mason
No Relationships to Disclose
 
Santosh Kesari
Honoraria - Caris Life Sciences; Novocure
Consulting or Advisory Role - Curtana
Speakers' Bureau - Caris Life Sciences; Novocure
Research Funding - BBI Healthcare; Celgene/Triphase Accelerator Corp; EpicentRx; Medicenna; Sanofi
 
Roger Stupp
Employment - Celgene (I)
Stock and Other Ownership Interests - Celgene (I)
Consulting or Advisory Role - Celgene (Inst); Debiopharm Group (Inst); Merck KGaA (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); UCB (Inst)
Travel, Accommodations, Expenses - Novocure
 
Dawit Gebremichael Aregawi
No Relationships to Disclose
 
David Eric Piccioni
No Relationships to Disclose
 
Patrick Roth
Honoraria - Novartis; Novocure
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Virometix
Research Funding - MSD (Inst)
 
Annick Desjardins
Stock and Other Ownership Interests - ISTARI Oncology
Consulting or Advisory Role - Celgene; Genentech/Roche
Research Funding - Celldex (Inst); Genentech/Roche (Inst); Lilly (Inst); Orbus Therapeutics (Inst); Pfizer (Inst); Symphogen (Inst); Triphase Accelerator Corp (Inst)
Patents, Royalties, Other Intellectual Property - AU 2013347945 - Method of Treating Solid Tumor w/Oncolytic Poliovirus licensed to Istari, a patent; CA 2,892,183 - Method of Treating Solid Tumor w/Oncolytic Poliovirus licensed to Istari, a patent; CN 201380070749.7 - Method of Treating Solid Tumor w/Oncolytic Poliovirus licensed to Istari, a patent; EP 13856989.2 - Method of Treating Solid Tumor w/Oncolytic Poliovirus licensed to Istari, a patent; HK 15112399.5 - Method of Treating Solid Tumor w/Oncolytic Poliovirus licensed to Istari, a patent; JP 2015-544130 Div: 2017-084158 - Method of Treating Solid Tumor w/Oncolytic Poliovirus licensed to Istari, and a patent; PCT/US17/023148 - Combination Therapy for Cancer Using Oncolytic Poliovirus licensed to Istari and Stock options, ISTARI Oncology; US 15/428510 - Method of Treating Solid Tumor w/Oncolytic Poliovirus licensed to Istari, a patent
 
Steven D. Reich
Consulting or Advisory Role - Array BioPharma; Artelo Biosciences; BeyondSpring Pharmaceuticals; Impact Biomedicines; Pfizer; Triphase Accelerator Corp
 
Marie-Laure Casadebaig
Employment - Celgene
Stock and Other Ownership Interests - Celgene
Travel, Accommodations, Expenses - Celgene
 
Ileana Elias
Employment - Celgene
Stock and Other Ownership Interests - Celgene
 
Benjamin Winograd
Employment - Celgene
 
Nancy Levin
Employment - Triphase Accelerator Corp
Stock and Other Ownership Interests - Amgen; Johnson & Johnson; Pfizer
 
Daniela Annenelie Bota
Consulting or Advisory Role - ERC; Primmune Therapeutics
Speakers' Bureau - Novocure